Anurag Singh, MD of Roswell Park explains what's next in research.
Roswell Park researchers present findings at ASTRO Annual Meeting
- Aspirin improved overall survival for patients with head/neck, lung cancers
- Patients in both studies also received radiation or chemoradiation therapy
- Future studies will help determine which patients benefit most
BUFFALO, N.Y. — What if a drug that sits in nearly everyone’s medicine cabinet could help extend the lives of some cancer patients? In companion presentations at the American Society for Therapeutic Radiation Oncology (ASTRO) Annual Meeting in Chicago, doctors from Roswell Park Comprehensive Cancer Center report new evidence that low-dose aspirin and other anti-inflammatories may improve survival in patients undergoing treatment for some head/neck and lung cancers.
The retrospective analyses are the first to suggest a benefit in overall survival for patients with either head and neck squamous cell carcinoma (HNSCC) or early-stage non-small cell lung cancer (NSCLC) who received non-steroidal anti-inflammatory drugs (NSAIDs) — most commonly, low-dose aspirin — alongside standard radiation therapy or chemoradiation therapy.